MHRA Approves UK’s First Nasal Spray for Anaphylaxis
An adrenaline nasal spray for the emergency treatment of anaphylaxis has been approved by the Medicines and Healthcare…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…
FDA Approves First Treatment for MAS in Still Disease
The FDA has approved the interferon gamma-blocking antibody emapalumab-lzsg (Gamifant) for the treatment of macrophage activation syndrome (MAS)…
More Days, More Resistance: Time to Rethink Antibiotics
“One of the most universally accepted beliefs around the world,” said Brad Spellberg, MD, chief medical officer at…
The majority of people in Wales support taking part in cancer clinical trials
A large majority of people in Wales support taking part in cancer clinical trials. According to a new…
United States Clinical Trial Investigative Site Network
Dublin, June 03, 2025 (GLOBE NEWSWIRE) — The “United States Clinical Trial Investigative Site Network Market, By Region,…
Chatbot Helps Users Adopt a Low FODMAP Diet
SAN DIEGO — Low fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) dietary advice has been shown to…
New Genetic Test Could Diagnose Brain Tumours in 2 Hours
Researchers at the University of Nottingham have developed a new genetic test that can diagnose brain tumours in…
Ubrogepant Eases Prodromal Migraine Symptoms
The clinical utility of the calcitonin gene–related peptide (CGRP) receptor antagonist ubrogepant may extend beyond the treatment of…
FDA Authorizes First Digital Therapeutic for Migraine
The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class…